CD274 and cancer: Peripheral blood markers such as baseline NLR and PLR have shown predictive value in the efficacy of anti-PD-1/PD-L1 inhibitors in advanced malignant tumors [49–54], as well as in the possibility of predicting the risk of irAE occurrence [15–17].